HPTN
(GlobalNewsWire) ICAP Receives New Award from NIH for HIV Prevention Trials Network
Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was featured in a Nov 30 article by Global News Wire which announced that ICAP has been awarded a seven-year grant from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the...
New PrEP Study Shows Significant Results for HIV Prevention
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
(MedicalXpress) ICAP’s Wafaa El-Sadr on HPTN 083 Injectable PrEP Results
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...